SUBSCRIBE
SUBSCRIBE

bluebird bio

NEWS
Here’s Why 5 Billionaire-Led Funds Gobbled Up 3.3 Million Shares of Celldex Stock
Drug Development
bluebird bio Surges as Pioneering Sickle Cell Gene Therapy Working for 13-Year-Old French Boy
June 15, 2015
 · 
5 min read
Astellas Pharma, Proteostasis Therapeutics Forge $1.2 Billion Genetic Disease Drug Development Pact
Drug Development
bluebird bio Defies RAC Panel’s Recommendation, Will Proceed With Two Planned Trials
June 10, 2015
 · 
5 min read
Biogen Idec Alzheimer's Drug Aducanumab Exceeds Expectations
Business
Celgene Will Focus On Anti-BCMA Drug, As It Returns CAR-T Pack to bluebird bio
June 4, 2015
 · 
4 min read
Astellas Pharma, Proteostasis Therapeutics Forge $1.2 Billion Genetic Disease Drug Development Pact
Business
bluebird bio Pads CAR T Arsenal With $131.5 Million Five Prime Pact
May 27, 2015
 · 
8 min read
Here’s Why 5 Billionaire-Led Funds Gobbled Up 3.3 Million Shares of Celldex Stock
Drug Development
Stock Soars as bluebird bio Gives Sneak Peek at Promising Sickle Cell Data
May 21, 2015
 · 
4 min read
Biogen Idec Alzheimer's Drug Aducanumab Exceeds Expectations
Drug Development
Investors Rejoice as bluebird bio Plots Road to First-Ever U.S. Gene Therapy Approval
May 19, 2015
 · 
5 min read
Biogen Idec Alzheimer's Drug Aducanumab Exceeds Expectations
Drug Development
bluebird bio’s Rare Blood Disorder Drug Tagged a Breakthrough by the FDA
February 2, 2015
 · 
2 min read
J.P. Morgan: Bluebird Bio Trading Near Historic Highs
Drug Development
J.P. Morgan: bluebird bio Soars On CEO’s Sickle Cell Data
January 15, 2015
 · 
2 min read
Analysts Not Sold On Medivation’s Xtandi as Breast Cancer Drug
BioCapital
bluebird bio’s New Blood Treatment Could Benefit Sickle Cell, Says Analyst
December 9, 2014
 · 
2 min read
Load More
AWARDS
  • 2022 Best Places to Work
JOBS
IN THE PRESS
bluebird bio Announces Updated Clinical Results from Ongoing Phase 1 Multicenter Study of LentiGlobin™ Gene Therapy in Severe Sickle Cell Disease at American Society of Hematology (ASH) Annual Meeting
bluebird bio announced that updated clinical results from HGB-206, the company’s ongoing Phase 1 multicenter study of its LentiGlobin gene therapy product candidate in patients with severe sickle cell disease (SCD), will be discussed in an oral presentation during the 59th Annual Meeting of the American Society of Hematology (ASH).
December 10, 2017
 · 
10 min read
bluebird bio Presents New Data from Clinical Studies of LentiGlobin Gene Therapy in Transfusion-Dependent β-Thalassemia at American Society of Hematology Annual Meeting
bluebird bio announced data from two studies of its LentiGlobin gene therapy product candidate in patients with transfusion-dependent β-thalassemia (TDT).
December 10, 2017
 · 
10 min read
bluebird bio and TC BioPharm Announce Strategic Collaboration to Research and Develop Gamma Delta CAR T Cell Product Candidates for Cancer Immunotherapy
Under the terms of the agreement, bluebird bio and TCB will collaborate to discover and develop CAR-engineered gamma delta T cells for cancer targets and indications.
December 7, 2017
 · 
7 min read
FDA Slaps Breakthrough Tag on Celgene, bluebird’s Multiple Myeloma CAR-T Drug
BTD designation and PRIME eligibility for bb2121 were based on preliminary clinical data from the ongoing phase 1 study CRB-401.
November 16, 2017
 · 
6 min read
bluebird bio Announces First Patient Treated in Northstar-3 (HGB-212), Phase III Study of LentiGlobin in Patients With Transfusion-Dependent β-Thalassemia (TDT) and β0/β0 Genotype
Study to enroll approximately fifteen adult, adolescent and pediatric patients.
November 16, 2017
 · 
6 min read
bluebird bio Reports Third Quarter 2017 Financial Results and Recent Operational Progress
bluebird bio reported business highlights and financial results for the third quarter ended September 30, 2017.
November 1, 2017
 · 
13 min read
bluebird bio To Present At Chardan Gene Therapy Conference
October 9, 2017
 · 
2 min read
bluebird bio Announces First Patient Treated With Second Anti-BCMA CAR T Bb21217 In CRB-402 Phase I Study In Patients With Relapsed/Refractory Multiple Myeloma
September 29, 2017
 · 
6 min read
bluebird bio Appoints Mary Lynne Hedley, Ph.D. To Board Of Directors
September 20, 2017
 · 
4 min read
bluebird bio Announces First Patient Treated In Expansion Cohort Of CRB-401, Phase I Study Of Anti-BCMA CAR T Therapy Bb2121
September 13, 2017
 · 
4 min read